The developmental and epileptic encephalopathies encompass a group of rare syndromes
characterised by severe drug-resistant epilepsy with onset in childhood and significant …

Background Approximately one-third of patients with epilepsy presents seizures despite
adequate treatment. Hence, there is the need to search for new therapeutic options …

Background Cannabidiol has been used for treatment-resistant seizures in patients with
severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to …

Summary Background Patients with Lennox-Gastaut syndrome, a rare, severe form of
epileptic encephalopathy, are frequently treatment resistant to available medications. No …

Background Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used
for various benign tumours associated with tuberous sclerosis complex. We assessed the …

Objective To update the 2004 American Academy of Neurology guideline for managing
treatment-resistant (TR) epilepsy with second-and third-generation antiepileptic drugs …

Nearly a quarter of patients with seizures have drug-resistant epilepsy. This review
examines how this diagnosis should be established and how to recognize …

Abstract Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is
associated with severe morbidity and increased mortality. Cannabis-based therapies have …

Despite the development of various new antiepileptic drugs (AEDs) since the early 1990s,
the available evidence indicates that the efficacy and tolerability of drug treatment of …

Lennox-Gastaut syndrome (LGS) is considered an epileptic encephalopathy and is defined
by a triad of multiple drug-resistant seizure types, a specific EEG pattern showing bursts of …